Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07136558) titled 'Evaluation of ICP-B794 in Patients With Advanced Solid Tumors' on Aug. 5.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Condition:
Advanced Solid Tumors
Intervention:
Drug: ICP-B794
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: August 2025
Target Sample Size: 410
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07136558
Published by HT Digital Content Services wit...